Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma. [electronic resource]
Producer: 20191101Description: 453-463 p. digitalISSN:- 1872-7980
- Anti-Inflammatory Agents, Non-Steroidal -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Diclofenac -- analogs & derivatives
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- drug effects
- Drug Synergism
- Energy Metabolism -- drug effects
- Genetic Predisposition to Disease
- Humans
- Melanoma -- drug therapy
- Mitogen-Activated Protein Kinases -- antagonists & inhibitors
- Mutation
- Phenotype
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Skin Neoplasms -- drug therapy
- Time Factors
- Vemurafenib -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.